OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
+$0.01 today
- Market cap
- $111.79M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
Volume 0.14M
Average 0.37M
Returns on capital
OnKure Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-105.9%
avg -8.1%
ROIC
-110.9%
avg -106.3%
ROA
-95.8%
avg -81.0%
Analysis
ROA is currently the strongest return metric at -95.8% versus its period average of -81.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Nicholas A. Saccomano | President, Chief Executive Officer & Director | USD 858K | 67 | 11.16K | 0.08% |
Samuel Agresta | Chief Medical Officer | USD 640.6K | 53 | 0 | <0.01% |
Jason A. Leverone | Chief Financial Officer | USD 591.2K | 52 | 18.50K | 0.14% |
Isaac Manke | Senior VP of Business Development & Director | USD 60.5K | 49 | 0 | <0.01% |
James Blake | Senior Vice President of Computational Drug Discovery | — | — | — | — |
Kevin S. Litwiler | Senior Vice President of DMPK & Clinical Pharmacology | — | — | — | — |
Mark L. Boys | Senior Vice President of Discovery Chemistry | — | — | — | — |
Rogan Nunn | General Counsel & Secretary | — | — | — | — |
Roberta Alton | Senior Vice President of Clinical Operations | — | — | — | — |
Dylan Hartley | Chief Scientific Officer | — | 57 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 21, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$5,630.13
Net Transaction Value
−$5,630.13
Net selling
Most Active
Saccomano Nicholas A
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 21, 26Sep 21, 2026 | Saccomano Nicholas A Direct | Sell | $258.8$258.76 |
| Sep 21, 26Sep 21, 2026 | Leverone Jason A. Direct | Sell | $898.2$898.21 |
| Jun 22, 26Jun 22, 2026 | Saccomano Nicholas A Direct | Sell | $378.1$378.08 |
| Jun 22, 26Jun 22, 2026 | Leverone Jason A. Direct | Sell | $1.3K$1,332.08 |
| Mar 23, 26Mar 23, 2026 | Leverone Jason A. Direct | Sell | $1.3K$1,251.11 |
| Mar 23, 26Mar 23, 2026 | Saccomano Nicholas A Direct | Sell | $357.5$357.46 |
| Dec 22, 25Dec 22, 2025 | Saccomano Nicholas A Direct | Sell | $258.2$258.19 |
| Dec 22, 25Dec 22, 2025 | Leverone Jason A. Direct | Sell | $896.2$896.25 |
Summary
Insiders reported 0 buys worth $0.00 and 8 sells worth $5,630.13 over the last 12 months. That adds up to net selling of $5,630.13. Saccomano Nicholas A was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does OnKure Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about OKUR's management, answered from reported figures.
Who manages OKUR?
OnKure Therapeutics, Inc. (OKUR) lists 10 active executives. The top listed executive is Isaac Manke, Senior VP of Business Development & Director.
Are OKUR insiders buying or selling?
Recent insider activity shows net buying of $12.50M.
Continue the stock analysis
Jump to another research area for this company.